Protection against BRCA1‐associated breast cancer or BRCA2‐associated gynecologic cancer was observed, but it was not statistically significant,45 in which relatively low incidence of BRCA2‐associated gynecologic cancers in the cohort (two in the surveillance cohort, zero in the RRSO cohort) limits conclusions regarding the impact of RRSO on the risk of subsequent BRCA2‐associated gynecologic cancers. The gene discussed is BRCA2; the disease is female reproductive organ cancer.